APOGEE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: APGE (Apogee Therapeutics, Inc.)
Last update: 46 minutes ago134.75
0.00 (0.00%)
| Previous Close | 134.75 |
| Open | 134.81 |
| Volume | 948,282 |
| Avg. Volume (3M) | 2,787,561 |
| Market Cap | 10,198,922,240 |
| Price / Book | 8.54 |
| 52 Weeks Range | |
| Earnings Date | 9 Nov 2026 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Apogee Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Venrock Adviser, Llc | 30 Jun 2026 | 8,493,321 |
| Hbk Investments L P | 30 Jun 2026 | 2,850,000 |
| Fmr Llc | 30 Jun 2026 | 2,493,137 |
| Janus Henderson Group Ltd. | 31 Mar 2026 | 2,360,596 |
| Driehaus Capital Management Llc | 30 Jun 2026 | 1,740,101 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 1,665,102 |
| Glazer Capital, Llc | 30 Jun 2026 | 1,641,042 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |